



Central Telephone/Exchange: + 41 (22) 791.2111
Direct : + 41 (22) 791 .1868
Email velayudhanr@who.int

In reply please refer to : V2-MTG-0027

Your reference :

Dr Tarek Abdallah El-Tayeb
Professor Photobiology
Scientific consultant of malaria project, INRAI
Cairo University
Gamaa Street
Giza
Egypt

28 January 2015

Dear Dr El-Tayeb,

Following the request of InRad Corporation and receipt of a dossier submission in 2014, the product SAFE was discussed by VCAG in the 3rd WHO Vector Control Advisory Group (VCAG) Meeting held at WHO/HQ, Geneva from 12 to 14 November 2014.

Please find below recommendations of the Vector Control Advisory Group. The report of the meeting including VCAG's assessment of SAFE will soon be published on the WHO website at: www.who.int/neglected_diseases/vector_ecology/VCAG/en/.

Considering the information available, the VCAG noted:

- *Based on the evidence presented, SAFE falls within a previously defined paradigm: Larvicides.*
- *Products falling within already defined paradigms do not need to demonstrate public health efficacy through community trials.*
- *This tool can be evaluated through WHOPES using the Guidelines for laboratory and field testing of mosquito larvicides.*
- *WHOPES evaluates product claims for commercially produced vector control products, therefore additional product development may be needed prior to being eligible for WHOPES review.*

Please contact the VCAG secretariat for any clarification.

Yours sincerely,

Dr Raman Velayudhan
Coordinator, Vector Ecology & Management
Department of Control of Neglected Tropical
Diseases (NTD)

Dr Abraham Mnzava
Coordinator, Vector Control Unit
Global Malaria Programme (GMP)